Adverse Reactions to Ferrlecit (Sodium Ferric Gluconate)
Ferrlecit causes adverse reactions in approximately 10-35% of patients, with the most common being gastrointestinal symptoms (nausea, vomiting, diarrhea in 35%), hypotension (29%), injection site reactions (33%), and cramps (25%), but true anaphylaxis is extremely rare (<0.5%). 1
Most Common Adverse Reactions
In Adults (≥10% incidence):
- Gastrointestinal: Nausea, vomiting, and/or diarrhea (35%)
- Injection site reactions (33%)
- Hypotension (29%)
- Cramps (25%)
- Hypertension (13%)
- Dizziness (13%)
- Abnormal erythrocytes (11%)
- Dyspnea (11%)
- Leg cramps (10%)
- Chest pain (10%) 1
In Pediatric Patients (6-15 years, ≥10% incidence):
- Hypotension (35%)
- Headache (24%)
- Hypertension (23%)
- Tachycardia (17%)
- Vomiting (11%) 1
Critical Safety Considerations
Hypersensitivity Reactions
The vast majority of reactions to intravenous iron are complement activation-related pseudo-allergy (CARPA/infusion reactions), NOT true IgE-mediated anaphylaxis. 2 True anaphylaxis occurs in approximately 0.5% of cases 3, though serious reactions have been reported including shock, loss of consciousness, and acute myocardial ischemia 1.
Dose-Related Risk
Individual doses exceeding 125 mg may be associated with higher incidence and/or severity of adverse events, including hypotension, nausea, vomiting, abdominal pain, diarrhea, dizziness, dyspnea, urticaria, chest pain, paresthesia, and peripheral swelling 1.
Hypophosphatemia
While hypophosphatemia is less common with ferric gluconate compared to ferric carboxymaltose (1% vs 58%), it can still occur with all parenteral iron preparations 3.
Management Algorithm
Pre-Administration Assessment:
- Question patients about prior reactions to ANY parenteral iron product 1
- Screen for major risk factors:
- Previous reaction to iron infusion
- Multiple drug allergies
- Severe atopy
- Systemic inflammatory diseases
- Concomitant ACE inhibitor use (1.6% vs 0.7% reaction rate) 1
- Contraindications: Early pregnancy, ongoing bacteremia 3, 1
During Infusion:
- Administer over 1 hour (standard protocol) 1
- Meticulous observation required throughout infusion 4
- Have emergency equipment immediately available
If Reaction Occurs:
For Mild-Moderate Infusion Reactions (most common):
- Stop infusion immediately
- Administer antihistamines (pheniramine maleate)
- Consider corticosteroids
- Provide supportive care (oxygen, IV fluids) 5
- Most reactions resolve rapidly with drug withdrawal 1
For Severe Hypersensitivity/Anaphylaxis:
- Stop infusion immediately
- Administer epinephrine (first-line treatment)
- Corticosteroids
- Aggressive supportive care 6
- Do not rechallenge with same formulation
Special Populations
Pregnancy:
Hypersensitivity reactions may cause fetal bradycardia—counsel pregnant women about this risk. Ferrlecit contains benzyl alcohol, which is rapidly metabolized by pregnant women but has caused adverse reactions in premature neonates 1.
Lactation:
Treatment with Ferrlecit is not recommended while breastfeeding 1.
Concomitant ACE Inhibitor Use:
Patients on ACE inhibitors have approximately 2-fold higher risk of reactions (1.6% vs 0.7%) 1.
Key Clinical Pitfalls
Do not assume all reactions are true allergies—most are CARPA reactions that may not recur with slower infusion or different formulation 2, 4
Previous reaction to iron dextran does NOT preclude use of ferric gluconate—case series demonstrate safe administration in patients with severe iron dextran reactions 7
Infection is NOT an absolute contraindication—withhold only in active bacteremia; studies show no significant increase in clinically important infections 3
Drug interaction: Ferrlecit reduces absorption of oral iron—do not co-administer 1
Higher doses (>125 mg) carry increased risk—consider splitting doses if total requirement exceeds this threshold 1